FUTURE OF HEALTHCARE
GoodRx | March 08, 2022
GoodRx a leading consumer-focused digital healthcare platform, announced that it had reached a definitive agreement to buy TherapeuticsMD's vitaCare Prescription Services. VitaCare is a technology and services platform that assists patients in overcoming primary barriers to brand medicine access and adherence. vitaCare, in particular, helps patients understand coverage, identify savings opportunities, and facilitate communication between physicians and payors. In addition, thanks to its extensive network of third-party pharmacies, the website also makes it easy to fill a prescription. With this acquisition, GoodRx will be able to assist more patients in receiving their prescriptions in a timely, cost-effective, and transparent manner, as well as staying on their prescribed medications for as long as they need to.
According to IQVIA, FDA, and DrFirst data, hardly half of the 500 million brand prescriptions generated yearly are completed. One crucial factor is that affordability is a significant barrier to access for many people, resulting in a lack of medication adherence among patients. According to CoverMyMeds, out of all the prescriptions filled in the United States last year, 29 percent of patients were delayed in receiving their medication due to insurance processing and physician communication delays. GoodRx thinks that vitaCare will have more tools to help streamline the prescription process from beginning to end, ensuring that patients have a clear path to accessing and affording the brand-name medications they require. Furthermore, the acquisition is expected to boost GoodRx's rapidly developing, high-margin Pharma Manufacturer Solutions products, which include drug knowledge, access, and adherence as well as unique capabilities.
“Over the past decade, GoodRx has helped millions of Americans afford generic medications, but brand medications remain too expensive for too many people. Pharma manufacturers want to help patients find affordable options, but too many consumers still face affordability challenges or complex reimbursement processes. With vitaCare, we aim to grow our reach and provide new tools for consumers and providers to help ensure that more patients can access relevant savings programs and navigate prior authorization requirements. In addition, we’re excited about the potential to help patients from the point of prescribing through their ongoing refills to ensure they can stay healthy.”
Doug Hirsch, co-CEO and co-founder of GoodRx
“We couldn’t be more excited to join GoodRx and be part of a team that is working to put affordable healthcare within reach for everyone,” said John Milligan, CEO at vitaCare Prescription Services. “Consumers come to vitaCare looking for a seamless, patient-first experience that will help them get the brand medications they are prescribed. Upon joining the GoodRx team, we hope to expand our network of pharmaceutical manufacturers and put even more therapies within reach for consumers.”
GoodRx has made a significant investment in offering low-cost brand-name drug solutions to consumers. GoodRx works with pharmaceutical manufacturers through our Pharma Manufacturer Solutions business to increase patient awareness of savings programs and prescriber access to these programs directly on our site, improving patient access to these programs and increasing adherence to the brand medications patients need to stay healthy. GoodRx offers a platform for manufacturers to engage big, high-intent audiences contextually appropriate to their products through GoodRx Health, our online health information portal. GoodRx now wants to expand its solutions for pharmaceutical producers with vitaCare to help patients gain access and adhere to their medications.
GoodRx has agreed to pay $150 million in cash for vitaCare, with an extra $7 million based on the company's financial success until 2023. The acquisition is scheduled to close in mid-2022, assuming all usual closing conditions are met. In 2022, taking the acquisition closes in the middle of the year, we project the transaction to add less than 1% to overall revenue and cut the adjusted EBITDA margin by about 2%. In future years, we expect the business to expand in revenue and profitability, but this will not substantially impact our long-term outlook.
Change Healthcare | December 23, 2020
Change Healthcare (Nasdaq: CHNG), today announced the effective presentation of its first cloud-based clinical apparatuses for radiologists and different specialties alongside its guide to help healthcare associations start their movement of clinical imaging to the cloud. This set-up of cloud-based clinical apparatuses will permit radiologists to have a more extensive arrangement of accessible imaging and more complete patient history when making an analysis. The capacities are helped by AI and empower secure conveyance to any gadget, anyplace. By engaging admittance to a more extensive arrangement of patient information, radiologists will currently have the option to get a more exhaustive perspective on the general patient, aiding a more precise and certain finding and correspondence and coordinated effort with the remainder of their patient's consideration group.
“Change Healthcare has a proven record of delivering its promises to our customers as we continue to innovate the industry’s first cloud-native enterprise imaging solution,” said Tracy Byers, senior vice president and general manager, Enterprise Imaging, at Change Healthcare. “This new suite of capabilities allows us to be there when and where our customers need us.”
Availability to imaging information at scale and conveyance of profitability enhancements for a standard rhythm has been hard to accomplish with the conventional model of programming facilitated on healthcare supplier workstations, workers, and organizations. Imaging documents are enormous, requiring superior frameworks and high level security, coming about in more slow appropriation of cloud arrangements in clinical imaging to date. The pandemic has quickened the requirement for cloud-based answers for radiologists and other healthcare colleagues to get to, see, break down, and share pictures and symptomatic data from anyplace, even on their telephone.
“Change Healthcare Enterprise Imaging Network™ Analytics has allowed us to achieve real-time review of our routine imaging data, without relying on reports three months in arrears or from various sources using their own source data ‘truth,’” said Matthew Brady, MD, president of Roper Radiologists PA. “Further, for niche quality or utilization questions, we can now perform on-the-fly review of the entire set of our data, without relying on painstaking limited subset samples.”
To help doctors and health systems begin their cloud-based medical imaging journey, Change Healthcare’s in-market and coming suite of cloud-native enterprise imaging solutions provides a security enabled single-platform portfolio to:
Centralize data and facilitate secure access with HITRUST-certified, SOC2-certified, and HIPAA-compliance supported solutions to help radiologists realize a quicker, more accurate workflow and images
Help ensure that radiologists have the latest tools available through the delivery of browser-based cloud-native software as a service (SaaS), enabling instant and automatic upgrades while retaining individual physician preferences for display and workflow
Enable image-sharing capabilities that allow healthcare organizations to support secure sharing of patient imaging files with other physicians, eliminating the need for the burning of CDs and relying on couriers, the mail, or patients to transfer the files, eliminating expense and delay
Empower the delivery of patient care through robust and intuitive analytics, letting doctors and healthcare organizations focus on improving care
About Change Healthcare
Change Healthcare (Nasdaq: CHNG) is a leading independent healthcare technology company, focused on accelerating the transformation of the healthcare system through the power of the Change Healthcare Platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.
SATO | March 08, 2021
SATO, a global pioneer in labeling solutions and the development of auto-ID, launched CT4-LX-HC compact desktop printer. The purpose of the launch is to address, at the point of care and throughout the supply chain, healthcare identification needs. It will be a great help for those struggling, especially due to the global pandemic, with complicated printer settings related to healthcare services.
The smart connectivity solution of SATO incorporates feedback from front-line operators of the industry. It helps in managing label designs and make streamlined printing of labels and avoid medical incidents. Genuine SATO consumables ensure operational accuracy. The CT4-LX-HC is also empowered with SATO’s great AEP on-board intelligence that changes the printer to a hub for coupling with outlying devices such as weight scales, thermometers, and more for modified integrations.
With COVID-19, there is a growing necessity to reinforce safety measures and confirm proper hygiene practices in daily processes to guard everyone’s well-being, whether they be customers, staff, or patients. The CT4-LX-HC features an anti-microbial casing that is antiseptic wipe down ready to safeguard hygiene when numerous users want to use its 4.3-inch touch screen exhibition in the same office.
SATO is a global auto-ID solutions provider for leading logistics, manufacturing, food & beverage, retail, and health care companies. With a bottom-up understanding of on-site use applications, SATO tags items with identifiers to improve supply chain flows of tomorrow by solving managerial and operational challenges of today. Industry pioneers with 80 years of expertise and a 5,400+ strong global workforce in 27 countries, SATO engineer’s solutions to boost accuracy, streamline operations, provide assurance and emotional connections, support sustainability initiatives, and extending value to the consumer. For the fiscal year ending March 31, 2020, it reported revenues of JPY 116,372 million.